ACIP Recommendations

Print
Related Pages

The ACIP develops recommendations on how to use vaccines to control disease in the United States.

The Committee’s recommendations are forwarded to CDC’s Director and once adopted become official CDC policy. These recommendations are then published in CDC’s Morbidity and Mortality Weekly Report (MMWR).

Recent Meeting Recommendations

ACIP approved the following recommendations by majority vote and they have been adopted by the CDC Director. They will be published in MMWR and reflected in CDC’s print and digital resources in the coming months.

June 26-28, 2024

ACIP approved the following recommendations by majority vote at its June 26-28, 2024 meeting:

RSV Vaccines – Adults

  • ACIP recommends adults 75 years of age and older receive a single dose of RSV vaccine.a,b
  • ACIP recommends adults 60–74 years of age and older who are at increased risk of severe RSV diseasec receive a single dose of RSV vaccine.a,b

aRSV vaccination is recommended as a single lifetime dose only. Persons who have already received RSV vaccination are NOT recommended to receive another dose.

bThese recommendations supplant the current recommendation that adults 60 years of age and older may receive RSV vaccination, using shared clinical decision-making. Adults 60–74 years of age who are not at increased risk of severe RSV disease are NOT recommended to receive RSV vaccination.

CCDC will publish Clinical Considerations that describe chronic medical conditions and other risk factors for severe RSV disease for use in this risk-based recommendation.

These recommendations have been adopted by the CDC Director on June 26, 2024 and are now official.

DTaP-IPV-Hib-HepB (Vaxelis®) Vaccine

  • ACIP recommends DTaP-IPV-Hib-HepB (Vaxelis®) should be included with PRP-OMP (PedvaxHIB®) in the preferential recommendation for American Indian and Alaska Native infants based on the Haemophilus influenzae type b (Hib) component.

This recommendation was adopted by the CDC Director on June 26, 2024 and is now official.

COVID-19 Vaccines

  • ACIP recommends 2024-2025 COVID-19 vaccines as authorized or approved by FDA in persons ≥6 months of age.

This recommendation was adopted by the CDC Director on June 27, 2024 and is now official.

Influenza Vaccines

  • ACIP reaffirms the recommendation for routine annual influenza vaccination of all persons aged ≥6 months who do not have contraindications.
  • ACIP recommends high-dose inactivated (HD-IIV3) and adjuvanted inactivated (aIIV3) influenza vaccines as acceptable options for influenza vaccination of solid organ transplant recipients aged 18 through 64 years who are on immunosuppressive medication regimens, without a preference over other age-appropriate IIV3s or RIV3.

These recommendations have been adopted by the CDC Director on June 27, 2024 and are now official.

Pneumococcal Vaccines

  • ACIP recommends PCV21 as an option for adults aged ≥19 years who currently have a recommendation to receive a dose of PCV.

This recommendation was adopted by the CDC Director on June 27, 2024 and is now official.

February 28-29, 2024
ACIP approved the following recommendation by majority vote at its February 28-29, 2024 meeting:

COVID-19 Vaccines

ACIP recommends persons ≥65 years of age should receive an additional dose of 2023–2024 Formula COVID-19 vaccine.

Chikungunya Vaccine

Recommendations for use of chikungunya vaccine among travelers:

ACIP recommends chikungunya vaccine for persons aged ≥18 years traveling to a country or territory where there is a chikungunya outbreak

In addition, chikungunya vaccine may be considered for the following persons traveling to a country or territory without an outbreak but with evidence of chikungunya virus transmission among humans within the last 5 years

  • Persons aged >65 years, particularly those with underlying medical conditions, who are likely to have at least moderate exposure* to mosquitoes, OR
  • Persons staying for a cumulative period of 6 months or more
*Moderate exposure could include travelers who might have at least 2 weeks (cumulative) of exposure to mosquitoes in indoor or outdoor settings.


Recommendations for use of chikungunya vaccine among laboratory workers:

ACIP recommends chikungunya vaccine for laboratory workers with potential for exposure to chikungunya virus

These recommendations have been adopted by the CDC Director on February 28, 2024 and are now official.

October 25-26, 2023

Meningococcal Vaccines

Pfizer’s MenABCWY vaccine may be used when both MenACWY and MenB are indicated at the same visit.*

*1) Healthy individuals aged 16–23 years (routine schedule) when shared clinical decision-making favors administration of MenB vaccination, 2) individuals aged 10 years and older at increased risk of meningococcal disease (e.g., due to persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia) due for both vaccines.
Mpox Vaccines

ACIP recommends vaccination* with the 2-dose§ JYNNEOS vaccine series for persons aged 18 years and older at risk for mpox

*This is an interim recommendation that ACIP will revisit in 2-3 years

§Dose 2 administered 28 days after dose 1

Persons at risk:

  • Gay, bisexual, and other men who have sex with men, transgender or nonbinary people who in the past 6 months have had one of the following:
    • A new diagnosis of ≥1 sexually transmitted disease
    • More than one sex partner
    • Sex at a commercial sex venue
    • Sex in association with a large public event in a geographic area where mpox transmission is occurring
  • Sexual partners of persons with the risks described in above
  • Persons who anticipate experiencing any of the above

Combined Immunization Schedules

Approve the Recommended Child and Adolescent Immunization Schedule, United States, 2024 and the Recommended Adult Immunization Schedule, United States, 2024.

These recommendations have been adopted by the CDC Director on October 26, 2023 and are now official.

February 22-24, 2023
ACIP approved the following recommendation by majority vote at its February 22-24, 2023 meeting:

  • ACIP recommends the 2-dose* JYNNEOS vaccine series for persons aged 18 years and older at risk of mpox during an mpox outbreak§.
    *Dose 2 administered one month after dose 1
    §Public health authorities determine whether there is an mpox outbreak; a single case may be considered an mpox outbreak at the discretion of public health authorities. Other circumstances in which a public health response may be indicated include ongoing risk of introduction of mpox into a community due to disease activity in another geographic area.

This recommendation has been adopted by the CDC Director and is now official.